EMA launches rolling review of Russia’s Sputnik V COVID-19 vaccine
Rolling review begins based on lab and clinical studies in adults
Read More
Tag: Sputnik V
RDIF confirms Sputnik V COVID vaccine’s efficacy
The Russian Direct Investment Fund has released a new analysis of data obtained 21 days after administering the first dose of the vaccine, showing efficacy of 91.4%
Read More
Russian says its ‘Sputnik V’ COVID-19 vaccine is 92% effective
Interim data analysis comes from phase III clinical trials in the Russian Federation
Read More
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
